CDK2 and cancer: Given that MCL1 is amplified in approximately 11% of cancers and overexpression of the protein is associated with chemoresistance (Beroukhim et al., 2010), the combination of a CDK2/9 inhibitor with a BCL2 family inhibitor presents an attractive therapeutic strategy for those cancers that may have an increased dependency on MCL1.